MétaCan
Menu
Back to cohort

Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease

2007· article· en· W2012042744 on OpenAlexafffundabout
Marie‐Christyne Cyr, Marie-France Beauchesne, Catherine Lemière, Lucie Blais

Bibliographic record

VenueBritish Journal of Clinical Pharmacology · 2007
Typearticle
Languageen
FieldMedicine
TopicChronic Obstructive Pulmonary Disease (COPD) Research
Canadian institutionsHôpital du Sacré-Cœur de MontréalUniversité de Montréal
FundersBayer CanadaCanadian Institutes of Health ResearchMinistère de la SantéMinistère de la Santé et des Services sociauxAstraZeneca CanadaAstraZenecaAmgen CanadaAmgenPfizerGlaxoSmithKline
KeywordsMedicineCOPDRate ratioExacerbationCohortConfidence intervalInternal medicineTheophyllinePulmonary diseaseCohort studyBronchodilatorAsthmaObstructive lung disease

Abstract

fetched live from OpenAlex

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Despite active research, none of the existing medications used to treat chronic obstructive pulmonary disease (COPD) has been shown to modify the long‐term decline in lung function. • Theophyllines have been recognized for their bronchodilating effects and anti‐inflammatory properties, but at the same time they are associated with the risk of adverse events due to their narrow therapeutic range and potential for drug interactions. • To our knowledge, no study has investigated the effects of theophylline on outcomes that can reflect the overall morbidity of COPD patients. WHAT THIS STUDY ADDS • The use of theophyllines is associated with a reduction in the rate of COPD exacerbations compared with long‐acting β 2 ‐agonists among COPD patients. • Theophyllines could be seen as an interesting alternative in the treatment of COPD, because they are much less expensive than long‐acting β 2 ‐agonists, and, from the patient's perspective, an oral formulation might be easier to take than an inhaled formulation. AIM To determine the effectiveness of theophyllines in real clinical practice on moderate to severe exacerbations. METHODS A cohort of 36 492 chronic obstructive pulmonary disease (COPD) patients aged ≥50 years was reconstructed from the health administrative databases of the province of Quebec, Canada, between 1 January 1995 and 31 December 2002 to compare users of theophyllines with users of inhaled corticosteroids (ICS) and users of long‐acting β 2 ‐agonists (LABA) on their rate of moderate to severe COPD exacerbations. RESULTS Users of theophyllines were found to be less likely than users of LABA [crude rates 84 vs. 91 per 100 patient‐years, adjusted rate ratio (RR) 0.89, 95% confidence interval (CI) 0.84, 0.95] and users of theophyllines plus ICS were found to be less likely than users of LABA plus ICS (crude rates 114 vs. 112 per 100 patient‐years, adjusted RR 0.89, 95% CI 0.87, 0.92) to have moderate to severe COPD exacerbations. Users of theophyllines were found to be more likely than users of ICS to have a COPD exacerbation (crude rates 84 vs. 77 per 100 patient‐years, adjusted RR 1.07, 95% CI 1.04, 1.10), and this association was even stronger among patients who had at least three exacerbations in the year prior to cohort entry (crude rates 273 vs. 213 per 100 patient‐years, adjusted RR 1.28, 95% CI 1.19, 1.38). CONCLUSION The use of theophyllines was found to be associated with a reduction in the rate of COPD exacerbations among all COPD patients, but to be less effective than ICS among patients with frequent exacerbations.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.336
Threshold uncertainty score0.643

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.363
Teacher spread0.344 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations37
Published2007
Admission routes3
Has abstractyes

Explore more

Same venueBritish Journal of Clinical PharmacologySame topicChronic Obstructive Pulmonary Disease (COPD) ResearchFrench-language works237,207